ClinicalTrials.gov
ClinicalTrials.gov Menu

Respiratory Syncytial Virus (RSV) Follow-Up Study (MK-0476-374)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01140048
Recruitment Status : Completed
First Posted : June 9, 2010
Results First Posted : October 5, 2012
Last Update Posted : July 20, 2016
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
This is a prospective, multicenter, observational study in participants who completed the 24-week, placebo-controlled MK-0476 Protocol 272 (NCT00076973) study of montelukast in the treatment of respiratory symptoms subsequent to RSV-induced bronchiolitis. The purpose of this study is to better understand the clinical and demographic correlates of asthma and atopic disorders in children (through the age of 6 years) with a history of severe RSV-induced bronchiolitis.

Condition or disease
Respiratory Syncytial Virus Bronchiolitis

Study Type : Observational
Actual Enrollment : 343 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: An Observational Follow-Up Study of Pediatric Patients Who Participated in a Previous Respiratory Syncytial Virus (RSV)-Induced Bronchiolitis Study of Montelukast
Study Start Date : October 2007
Actual Primary Completion Date : October 2011
Actual Study Completion Date : October 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Group/Cohort
All Enrolled Participants
All participants who completed Protocol 272 and were enrolled in Protocol 374



Primary Outcome Measures :
  1. Percentage of Participants With Asthma at 6 Years of Age: Overall and by Prognostic Factor [ Time Frame: At 6 years of age ]

    Asthma was defined as a positive response to the Epidemiology Questionnaire item "Has your child had wheezing or whistling in the chest in the past 6/12 months?" for the period of 12 months prior to age 6 years.

    Prognostic factors for asthma at age 6 years were derived from baseline characteristic, disease characteristic and family history data, and were identified by a forward stepwise regression model.



Secondary Outcome Measures :
  1. Percentage of Participants With Atopic Disorders at 6 Years of Age: Overall and by Prognostic Factor [ Time Frame: At 6 years of age ]

    Atopic disorders include allergic rhinitis (AR) and/or atopic dermatitis (AD). Atopic disorders was defined as a positive response to the Epidemiology Questionnaire item "In the past 6/12 months, has your child had a problem with sneezing or runny or blocked nose when he/she did not have a cold or the flu?" for AR and/or a positive response to both of the following items for AD: "Has your child had an itchy rash which was coming and going at any time in the past 6/12 months?" and "Has this itchy rash at any time affected any of the following places: the folds of the elbows, behind the knees, in front of the ankles, under the buttocks, or around the neck, ears, or eyes?" for the period of 12 months prior to age 6 years.

    Prognostic factors for atopic disorders at age 6 years were derived from baseline characteristic, disease characteristic and family history data, and were identified by a forward stepwise regression model.


  2. Percentage of Participants With Use of Chronic Asthma Therapy at 6 Years of Age: Overall and by Prognostic Factor [ Time Frame: At 6 years of age ]

    Use of Chronic Asthma Therapy for the period of 12 months prior to the age of 6 years was defined by clinical review of reported concomitant medications.

    Prognostic factors for use of chronic asthma therapy at age 6 years were derived from baseline characteristic, disease characteristic and family history data, and were identified by a forward stepwise regression model.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Months to 6 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The study sample includes participants who completed all visits of Protocol 272 from approximately 38 study sites worldwide. Participants enrolled in Protocol 272 were 3- to 24-month-old children with their first or second episode of "severe" RSV-induced bronchiolitis.
Criteria

Inclusion Criteria:

  • successfully completed MK-0476 Protocol 272
  • had RSV-induced bronchiolitis at entry into Protocol 272

Exclusion Criteria:

  • had developed or had been diagnosed with any illness or congenital disorder that could be immediately life threatening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01140048


Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Monitor Merck Sharp & Dohme Corp.

Publications of Results:
Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT01140048     History of Changes
Other Study ID Numbers: 0476-374
2010_026 ( Other Identifier: Merck Registration ID )
MK-0476-374 ( Other Identifier: Meck Protocol ID )
First Posted: June 9, 2010    Key Record Dates
Results First Posted: October 5, 2012
Last Update Posted: July 20, 2016
Last Verified: July 2016

Keywords provided by Merck Sharp & Dohme Corp.:
Asthma

Additional relevant MeSH terms:
Bronchiolitis
Bronchitis
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections